Butyrate (Sodium/Calcium Butyrate) 用于 Ulcerative Colitis (UC)
CRecent 90-day RCT (140 IBD participants) showed oral butyrate improved Crohn's symptoms and QoL. Earlier studies on butyrate enemas showed benefit in distal UC.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbutyrate\u0026condition\u003Dibd\u002Dulcerative\u002Dcolitis';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
结论
Recent 90-day RCT (140 IBD participants) showed oral butyrate improved Crohn's symptoms and QoL. Earlier studies on butyrate enemas showed benefit in distal UC.
Key Study Findings
Randomized Controlled Trial
n=140
Double-blind
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study …
Dose: None
vs: placebo plus conventional therapy
Outcome: clinical disease activity and fecal calprotectin
效果: None
p=0.013
研究人群: IBD patients (60 Crohn's disease, 80 ulcerative colitis)
basic science
Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA.
Dose: Lactobacillus reuteri E9 (dose not specified)
vs: Placebo
效果: None
< 0.05
In Vitro
Gut microbiota-derived butyrate mediates the anticolitic effect of indigo supplementation through regulating CD4+ T cell …
Dose: None
vs: UC animal and clinical samples
Outcome: Intestinal inflammation via CD4+ T cell regulation
效果: None
None
研究人群: UC murine model + UC patient samples
Randomized Controlled Trial
n=36
12 weeks
Double-blind
Effects of Short Chain Fatty Acid-Butyrate Supplementation on the Disease Severity, Inflammation, and Psychological Factors …
Dose: 600 mg/kg with main meal
vs: Placebo (rice starch)
Outcome: Mayo score, ESR, anxiety/depression (HADS)
效果: Mayo score -2.33 vs +0.22
p<0.001 (Mayo, dep, GHQ)
研究人群: Active ulcerative colitis patients
In Vitro
Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.
Dose: None
vs: LPS-stimulated RAW264.7 cells
Outcome: Macrophage polarization (M1 to M2 shift)
效果: None
None
研究人群: RAW264.7 macrophage cell line
In Vitro
Effects of Lactobacillus paracei JY062 Postbiotic on Intestinal Barrier, Immunity, and Gut Microbiota.
Dose: 5 mg/mL
vs: LPS-treated cell models
Outcome: Intestinal barrier function and gut microbiota
效果: None
None
研究人群: Caco-2 cells, RAW264.7 macrophages, fecal fermentation
Key Statistics
3
研究数量
390
受试者
↑
Positive
C
等级
Referenced Papers
Digestive and liver …
2026
5 次引用
Phytomedicine : international …
2025
17 次引用
Phytomedicine : international …
2025
13 次引用
Annals of medicine
2025
12 次引用
iMeta
2025
10 次引用
Journal of nutrition …
2025
9 次引用
Molecular medicine (Cambridge, …
2025
8 次引用
Nutrients
2025
7 次引用
Biomarker research
2025
6 次引用
Journal of proteome …
2025
5 次引用
Translational research : …
2025
4 次引用
Phytomedicine : international …
2025
4 次引用
Frontiers in cellular …
2025
4 次引用
Langenbeck's archives of …
2025
3 次引用
Mediators of inflammation
2025
2 次引用
Nature communications
2025
1 次引用
Frontiers in bioscience …
2025
PloS one
2025
Biochimica et biophysica …
2024
90 次引用
ACS nano
2024
89 次引用
Lipids in health …
2024
48 次引用
ACS nano
2024
38 次引用
Journal of agricultural …
2024
36 次引用
Gut microbes
2024
32 次引用
Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
Systematic Review
Microbiological research
2024
31 次引用
Journal of agricultural …
2024
14 次引用
Journal of agricultural …
2024
12 次引用
Gut microbes
2024
11 次引用
Poultry science
2024
9 次引用
Scientific reports
2024
9 次引用
Frontiers in pharmacology
2024
2 次引用
Journal of animal …
2024
Nutrients
2023
162 次引用
Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review.
Systematic Review
Gut microbes
2023
30 次引用
Cells
2023
18 次引用
Immunological investigations
2023
13 次引用
Nutrients
2023
9 次引用
Lipids in health …
2023
7 次引用
Journal of agricultural …
2022
202 次引用
Clinical science (London, …
2022
180 次引用
Microbiology spectrum
2022
146 次引用
Gut microbes
2022
107 次引用
Frontiers in cellular …
2022
88 次引用
Gut microbes
2022
60 次引用
Nutrients
2022
54 次引用
Frontiers in cellular …
2022
15 次引用
International journal of …
2022
10 次引用
Neurogastroenterology and motility
2020
176 次引用
Frontiers in immunology
2019
3034 次引用
Terapevticheskii arkhiv
2019
50 次引用
World journal of …
2019
45 次引用
World journal of …
2018
539 次引用
Current pharmaceutical design
2018
108 次引用
Journal of Crohn's …
2018
91 次引用
Journal of animal …
2018
15 次引用
Cell host & …
2017
399 次引用
Comprehensive Physiology
2017
245 次引用
Journal of gastroenterology
2016
49 次引用
Proceedings of the …
2014
1853 次引用
Gut
2014
1657 次引用
World journal of …
2014
23 次引用
Gut
2013
311 次引用
Clinical nutrition (Edinburgh, …
2010
177 次引用
Journal of AOAC …
2004
Resistant starches.
Other
Current opinion in …
2000
28 次引用
Diseases of the …
1998
26 次引用
Digestive diseases and …
1997
254 次引用
Bailliere's clinical gastroenterology
1997
26 次引用
Diseases of the …
1995
31 次引用
The Journal of …
1994
29 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 150-600 mg/day sodium or calcium butyrate
- ibdsupport:
- 300-600 mg three times daily (900-1,800 mg/day)
- butyrateenema:
- 100 mM butyrate enema for distal UC (clinical setting only)
上限： No established upper limit for oral supplements; most studies use 600-4,000 mg/day
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Positive | 140 |
| Lactobacillus reuteri E9 (dose not specified) | -- | Positive | -- |
| None | -- | Positive | -- |
| 600 mg/kg with main meal | 12 weeks | Positive | 36 |
| None | -- | Positive | -- |
| 5 mg/mL | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | 212 |
最佳服用时间： With meals; enteric-coated formulations recommended to reach the colon
Safety & Side Effects
已报告的副作用
- ⚠ Unpleasant taste/odor (butyric acid has a strong rancid butter smell)
- ⚠ Mild GI discomfort (nausea, bloating)
- ⚠ Belching with butyric acid odor
- ⚠ Enteric-coated formulations reduce taste issues
已知相互作用
- ● 5-ASA medications (mesalamine) — additive anti-inflammatory effect (potentially beneficial in IBD)
- ● No significant adverse drug interactions known
可耐受最高摄入量： No established upper limit for oral supplements; most studies use 600-4,000 mg/day
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Butyrate (Sodium/Calcium Butyrate) help with Ulcerative Colitis (UC)?
Based on 3 studies with 390 participants, there is limited but promising evidence that Butyrate (Sodium/Calcium Butyrate) may support Ulcerative Colitis (UC) management. Our evidence grade is C (Some Evidence).
How much Butyrate (Sodium/Calcium Butyrate) should I take for Ulcerative Colitis (UC)?
Studies have used various dosages. A commonly studied range is 150-600 mg/day sodium or calcium butyrate. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Butyrate (Sodium/Calcium Butyrate)?
Reported side effects may include Unpleasant taste/odor (butyric acid has a strong rancid butter smell), Mild GI discomfort (nausea, bloating), Belching with butyric acid odor, Enteric-coated formulations reduce taste issues. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Butyrate (Sodium/Calcium Butyrate) and Ulcerative Colitis (UC)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 390 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 Ulcerative Colitis (UC)
Butyrate (Sodium/Calcium Butyrate) 用于其他健康状况
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。